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The cancer stem cell (CSC) hypothesis proposes that CSCs are the root of cancer. CSC-targeted therapies
may prevent cancer relapse and provide more effective treatment. The expression of aldehyde
dehydrogenase 1, as assessed by the Aldefluor assay, has been recognized as a marker of CSCs in breast
cancer. Inhibitors of DNA-binding proteins (IDs) have an important role in stem cell differentiation. In
this study, we examined IDs necessary for the regulation of stem properties in Aldefluor
pos 4T1 cells.
When the expression profile of IDs in Aldefluor
neg and Aldefluor
pos 4T1 cells was compared, qRT-PCR
analysis showed that ID4 expression was highly upregulated in Aldefluor
pos 4T1 cells. In addition,
knockdown of ID4 expression suppressed the properties of CSCs, including their sphere-forming ability
and side population phenotype. The findings suggest that ID4 may be a therapeutic target for the
treatment of advanced breast cancer.
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Cancer stem cells (CSCs) are a subpopulation of tumor
cells that possess tumor initiation and self-renewal capacity.
CSCs may be responsible for resistance to conventional
therapies that can frequently lead to cancer metastasis and
recurrence [1-3]. If so, CSC specific therapies may prevent
cancer relapse and completely destroy cancer at the origin.
Aldehyde dehydrogenase (ALDH) is a detoxifying enzyme
responsible for oxidizing intracellular aldehydes. The enzyme
plays an important role in multiple biological activities. The
expression of ALDH1, as assessed by the Aldefluor assay,
has been recognized as a marker for normal and malignant
human mammary stem cells [4]. Especially, breast CSCs with
elevated ALDH activity are highly tumorigenic in a NOD/
SCID xenograft model [4]. Clinical data suggest that high
ALDH1 expression is correlated with poor clinical outcome
in breast cancer patients [4-6]. Collectively, these studies
support the view that ALDH1 may be a relevant CSC marker
in breast cancer.
Inhibitors of DNA-binding proteins (IDs) are transcription
factors that antagonize the DNA-binding capacity of basic
helix-loop-helix factors. IDs regulate cell cycle and cell
differentiation, and have an important role in the control
of stem cell self-renewal [7,8]. Elevated expression of IDs
in neural stem cells increases self-renewal and proliferation
[9]. Furthermore, IDs expression is elevated in various tumor
cell lines [10,11]. Together, these studies suggest a possible
link between CSCs and IDs expression. The 4T1 cell line
is widely considered to be one of the best mouse mammary
cancer cell lines for the study of human cancer progression
[12,13]. Therefore, in this study, we used 4T1 mouse mammary
cancer cells to investigate IDs necessary for cancer stemness,
with the goal of determining those IDs that could be feasible
targets for stem-specific cancer therapy.
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Materials and Methods
Cell culture
The 4T1 mouse mammary cancer cell line was cultured
in DMEM (Invitrogen, Grand Island, NY, USA) containing 10%
fetal bovine serum and 1% penicillin/Streptomycin (Invitrogen)
as previously described [14].
Flow cytometry
Cell sorting and side population (SP) analysis were performed
using FACS Aria and FACS LSRII machines (Becton Dickinson,
Franklin Lakes, NJ, USA), respectively. FACS data were analyzed
using Flowjo software (Tree star, Ashland, OR, USA). The
Aldefluor kit (Stem Cell Technologies, Vancouver, BC, Canada)
was used to isolate cell populations with elevated ALDH1
activity, according to the manufacturer's instructions.
Quantitative reverse-transcription-PCR (qRT-PCR)
qRT-PCR was performed using SYBR green PCR master
mix (Applied Biosystems, Foster City, CA, USA) and the ABI
7300 real-time PCR system according to the manufacturer's
instructions. Mouse mRNA levels were normalization to mouse
hypoxanthine-guanine phosphoribosyltransferase (HPRT). The
primer details sets were:
ID1: 5’-TGCTCTCGGTTCCCCAGGGG-3’ (forward)
ID1: 5’-CCCACTGGACCGATCCGCCA-3’ (reverse)
ID2: 5’-TCTGGGGGATGCTGGGCACC-3’ (forward)
ID1: 5’-GCTTGGGCATCTCCCGGAGC-3’ (reverse)
ID3: 5’-CTACTCGCGCCTGCGGGAAC-3’ (forward)
ID1: 5’-CGGCTCTGCCAGGACCACCT-3’ (reverse)
ID4: 5’-GCTCGTGCCTACCATCCCGC-3’ (forward)
ID1: 5’-GGTGGCGGCTGTCTCAGCAAA-3’ (reverse)
ABCG2: 5’-GAACATCGGCCTTCAAAGAGC-3’ (forward)
ABCG2:  5’-GGCACCAATAATAAGCCCCAGT-3’ (reverse)
ABCB1: 5’-CAACAGCCGGGCCGTGTCTC-3’ (forward)
ABCG2:  5’-GCTGCTTCTGCCCACCCGAC-3’(reverse)
ABCA1: 5’-CTCCCGTGCCAACCTGGCAG-3’ (forward)
ABCG2:  5’-GCCAGGCTACGCACAGCACA-3’ (reverse)
ABCA2: 5’-GCATTCAAACTGAGGCACCA-3’ (forward)
ABCG2:  5’-GACAGCCGTAATCGGTACTCCT-3’ (reverse)
ABCC1: 5’-TCGCCATGACCGGGGCTACA-3’ (forward)
ABCG1:  5’-GGGCTCGGAGCACTCCCTGA-3’ (reverse)
ABCC2: 5’-GGAGGCAGTACACGATTGGAGA-3’ (forward)
ABCG2: 5’-GGTCACGTCCATTAGCTTCCTGG-3’ (reverse)
ABCC3: 5’-GATCCTGAACGGCATCAAAGTG-3’ (forward)
ABCG3:  5’-TCCCTTTCACCTGCTCCAAGA-3’ (reverse)
HPRT: 5’-GCCTAAGATGAGCGCAAGTTG-3’ (forward)
HPRT:  5’-TACTAGGCAGATGGCCA CAGG-3’ (reverse)
Immunoblot analysis
Immunoblot analysis was performed as previously described
[14]. Antibodies to the following proteins were used: ID4
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) and β-
actin (Sigma-Aldrich, St. Louis, MO, USA).
Tumorsphere culture
Tumorsphere culture was performed in low attachment
dishes (Corning, New York, NY, USA), supplemented with
B27 (Invitrogen), 20 ng/mL epidermal growth factor (EGF),
20 ng/mL basic fibroblast growth factor (bFGF; Peprotech,
Rocky Hill, NJ, USA) and 4 g/mL heparin (Sigma-Aldrich).
After 7-day culture, wells were examined under an inverted
microscope at ×50 magnification, and the number and
diameter of spheres was counted for in independent fields
per well using the Image-Pro Plus program (Media Cybernetics,
Silver Spring, MD, USA).
Small interfering RNA (siRNA)
siRNA specific to ID4 (Cat no: M-043687-01) and non-
targeting siRNA (Cat No: D-001206-13-05) were purchased
from Dharmacon (Lafayette, CO, USA). Transfection was
performed using DharmaFECT (Dharmacon), according to
the manufacturer’s instructions. Cells were treated for 2 days
with siRNA at a final concentration of 100 nM.
Statistical analysis
All experiments were done three or more times, and the
results are expressed as mean±SD. Statistical analyses of these
data were done using an unpaired Student's t test for
parametric analysis or the Mann-Whitney U test for
nonparametric analysis.
Results
Aldefluor
pos cell population has high ID4 expression
The expression of ALDH1, as assessed by the Aldefluor
assay, has been recognized as a CSC marker in breast cancer
[4]. To evaluate IDs expression in CSC population characterized
by high ALDH1 activity, we compared the expression of IDs
in Aldefluor
neg and Aldefluor
pos cell populations sorted from
4T1 cells (Figure 1A). qRT-PCR analysis showed a significant
increase (approximately 2.5-fold) of ID4 gene expression but
no significant change of ID1, ID2, and ID3 expression in
Aldefluor
pos 4T1 cell population compared to the Aldefluor
neg
4T1 cell population (Figure 1B).Role of ID4 in mammary cancer stem cells 335
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Knockdown  of  ID4  inhibits  tumorsphere  forming
ability
To investigate whether ID4 influences the properties of CSCs,
siRNA technology was used to knockdown ID4 in 4T1 cells.
qRT-PCR and immunoblot analyses showed that ID4
expression was efficiently suppressed in 4T1 cells transfected
with ID4 targeted siRNA (siID4), whereas non-transfected cells
(None) and cells transfected with control siRNA (siCON) had
similar ID4 expression (Figures 2A and 2B). The sphere forming
assay is considered to demonstrate the self-renewing ability
of stem cells. ID4 knockdown in 4T1 cells reduced the
efficiency of formation of tumorsphere more than 100 min
diameter (Figure 2C).
Knockdown of ID4 reduces SP fractions and ABCC3
expression
The SP phenotype is associated with the characteristics
of CSCs [15]. To determine whether ID4 affects the SP fraction,
cells were stained with Hoechst 33342, which is actively
extruded by verapamil-sensitive ATP-binding cassette (ABC)
transporter. Flow cytometry analysis showed an approximately
2.6-fold decrease of the SP fraction in ID4 siRNA-transfected
Figure 2. Knockdown of ID4 expression suppresses tumorsphere-forming ability. (A and B) qRT-PCR and immunoblot analysis for
ID4 in control (Non, non-transfected cells), siCon (control siRNA) or siID (ID4 siRNA)-transfected 4T1 cells. (C) Effects of ID4
knockdown on tumorsphere formation in 4T1 cells. After siRNA transfection under adherent conditions, cells were detached and
suspension cultured under serum free conditions for 7 days. Values are mean±SD. *P<0.05 is a statistically significant difference.
Scale bar=100 µm.
Figure 1. The Aldefluor
pos cell population has high ID4 expression. (A) The dot plots show the percentage of Aldefluor
neg (R1) and
Aldefluor
pos (R2) cells from 4T1 cells. (B) The expression profile of IDs in Aldefluor
neg and Aldefluor
pos 4T1 cells. qRT-PCR was
performed using primers for IDs. Values are mean±SD. *P<0.05 is a statistically significant difference.336 Se-Jin Park et al.
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4T1 cells, compared with their counterparts (Figure 3A). Recent
evidence suggests that the SP fraction highly expresses the
ABC transporters [15]. We also examined whether knockdown
of ID4 affects the expression of ABC transporters in 4T1 cells.
qRT-PCR analysis showed an approximately 3-fold decrease
of ABCC3 expression but no significant change of the other
ABC transporter’s expression. 
IDs expression is elevated in recurrent breast cancers
The CSC hypothesis proposes that CSCs are the root of
cancer and contribute to cancer recurrence [1,2]. In silico
analysis of results from large clinical microarray studies [16,17]
showed ID4 mRNA levels correlated positively with recurrence
in human breast cancer (Figure 4).
Discussion
IDs have been recognized as prominent regulators of stem
cell fate decisions [18,19]. In this study, we investigated the
IDs that are necessary for the regulation of CSCs in 4T1
Figure 3. ID4 knockdown affects SP fraction and ABCC3 expression. (A) Representative SP phenotype from 4T1 cells transfected
with non-specific control siRNA (siCON) of ID4-targeted siRNA (siID4). The SP fraction, which actively pumps out the Hoechst dye,
is identified as the poorly staining cell population (black triangle) that largely disappears when the ABC transporters are inhibited
with verapamil. (B) qRT-PCR analysis of ABC transporters expression in 4T1 cells following transfection with siCON or siID4.
Values are mean±SD. *P<0.05 is a statistically significant difference.
Figure 4. ID4 mRNA expression in human breast tumors as a function of recurrent status (extracted from Sorlie et al [16] and Finak
et al [17]). In silico analysis of published clinical microarray data was performed using database and analysis tools (http://
www.oncomine.org).Role of ID4 in mammary cancer stem cells 337
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mouse mammary cancer cells. To our best knowledge, our
study is the first experimental report showing that inhibition
of ID4 may attenuate the maintenance and expansion of
breast CSCs.
High ID4 expression in glioma is implicated in malignant
cancer progression [20]. Several recent studies reported that
experimental overexpression of ID4 dedifferentiates Ink4a/
Arf
−/− mouse astrocytes and glioma cells to glioma stem-like
cells (GSCs) and enhances drug resistance of GSCs [21,22].
Collectively, the previous and present data provide evidence
that high ID4 expression enhances properties of stem cells
in cancers.
We especially observed a decrease of the SP fraction in
ID4 siRNA-transfected 4T1 cells compared with their
counterparts. SP cells can rapidly efflux lipophilic fluorescent
dyes to produce a characteristic profile based on fluorescence-
activated flow cytometric analysis. The SP phenotype might
facilitate the enrichment of CSCs and SP fractions have the
capacity for both self-renewal and proliferation and to be
largely responsible for in vivo malignancy [23]. The biological
basis for the differential efflux of these dyes out of the cells
is associated with the presence of transmembrane proteins,
such as ABC transporters [24]. Several transporters may
contribute to the malignant SP phenotype, such as ABCG2
and ABCA3 in the neuroblastoma or leukemia SP fraction
[15,25]. It has been reported that the plasma expression of
ABCC2 and ABCC3 may contribute to the chemoresistance
phenotype of hepatocellular carcinoma [26]. Therefore, we
examined whether ID4 affects the expression of an ABC
transporter, after confirming that knockdown of ID4 expression
suppressed the SP phenotype in 4T1 cells. Our results show
that knockdown of ID4 expression decreased ABCC3
expression compared with controls. These data suggest that
ID4 expression stimulates cultured mouse mammary cancer
cells to adopt characteristics of stem cells, partly through the
regulation of ABCC3 expression. However, the present data
do not fully explain the molecular mechanisms of ID4 in
cancer stemness. Thus, we are still investigating possible
mechanisms.
In summary, the therapeutic targeting of ID4 may be useful
for the treatment of breast CSCs. We predict that the further
characterization of the specific role of ID4 in CSC signaling
complexes will aid in the development of more effective
cancer therapies.
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